Tardive dystonia is a delayed, often persistent movement disorder caused by chronic exposure to dopamine receptor blocking agents, most commonly antipsychotics and metoclopramide. It belongs to the family of tardive syndromes but is clinically and prognostically distinct from tardive dyskinesia: dystonia produces sustained, twisting, often painful postures rather than the choreiform, stereotyped oral-buccal-lingual movements of classic tardive dyskinesia. Recognition matters because tardive dystonia is more disabling, more likely to involve younger men, and less responsive to standard tardive dyskinesia treatments. Although DSM-5-TR groups it under medication-induced movement disorders, management draws on the movement disorders literature, with vesicular monoamine transporter 2 inhibitors, botulinum toxin, anticholinergics, and deep brain stimulation occupying distinct roles. The clinical bottom line: identify the offending agent early, document a clear motor exam, and treat aggressively before postures become fixed.

Tardive dystonia is uncommon but consistently observed in cohorts of patients exposed to dopamine receptor blocking agents for months to years. Most epidemiologic data derive from antipsychotic-treated populations, with smaller signals from metoclopramide and prochlorperazine.

Prevalence and incidence

• Prevalence of tardive dystonia among chronic antipsychotic users is estimated at roughly 1-4%, with higher rates in long-term inpatient cohorts.^[1-2]
• The broader category of tardive dyskinesia affects approximately 20-30% of patients on first-generation antipsychotics and 7-13% of those on second-generation agents, of whom a minority develop predominantly dystonic features.^[2-3]
• Annual incidence of tardive dystonia in newly exposed adults is estimated at less than 1% per year, but cumulative incidence rises with duration of exposure.^[1]

Demographic and clinical risk factors

• Younger age at exposure, in contrast to classic tardive dyskinesia, where older age is the dominant risk factor.^[1,4]
• Male sex shows a modest predominance in tardive dystonia, the opposite pattern from tardive dyskinesia.^[1,4]
• Cumulative antipsychotic exposure, particularly with high-potency first-generation agents such as haloperidol and fluphenazine.^[2,4]
• History of acute dystonic reactions early in treatment.^[1,4]
• Comorbid mood disorder or intellectual disability, both reported as independent risk factors in cohort studies.^[1-2]
• Coexisting tardive dyskinesia in roughly half of patients, suggesting shared pathophysiology with phenotypic divergence.^[1,4]

Offending agents

• All DRBAs can cause tardive dystonia, including high-potency first-generation antipsychotics, lower-potency phenothiazines, and second-generation antipsychotics.^[2,4]
• metoclopramide 10 mg PO and prochlorperazine, used as antiemetics or for gastroparesis, are an underrecognized cause and carry an FDA boxed warning for tardive movement disorders.^[5]
• clozapine carries the lowest reported risk and is often used as a switch agent when tardive dystonia emerges on another antipsychotic.^[6]

The pathophysiology of tardive dystonia is incompletely understood. The dominant model is chronic postsynaptic D2 receptor blockade producing maladaptive plasticity in basal ganglia circuits, with downstream changes in striatal output and cortical motor control.

Neurochemical hypotheses

• Dopamine receptor supersensitivity: chronic D2 blockade upregulates striatal D2 receptors, producing exaggerated postsynaptic responses to endogenous dopamine when blockade is reduced.^[4,7]
• Imbalance between direct (D1-mediated) and indirect (D2-mediated) basal ganglia pathways, favoring sustained involuntary motor output.^[7]
• Striatal cholinergic interneuron dysfunction, supporting the clinical observation that anticholinergics often help tardive dystonia while worsening tardive dyskinesia.^[4,7]
• Oxidative stress and free-radical injury to striatal medium spiny neurons from sustained antipsychotic exposure, a hypothesis supported by animal models but not definitively confirmed in humans.^[7]

Structural and functional findings

• Neuroimaging in tardive dystonia is generally unremarkable on routine MRI, and the diagnosis remains clinical.^[4]
• Functional imaging studies suggest altered striatal and pallidal activity, with abnormalities in the internal globus pallidus that parallel findings in primary dystonia.^[7-8]
• The internal globus pallidus is the principal surgical target for deep brain stimulation in refractory cases, consistent with its central role in dystonic circuitry.^[8]

Genetics and predisposition

• Family and twin data suggest genetic vulnerability to tardive syndromes broadly, with candidate variants in DRD2, DRD3, HTR2A, and genes regulating oxidative stress reported but not consistently replicated.^[7]
• CYP2D6 poor metabolizer status has been associated with higher antipsychotic exposure and may contribute to risk, though the clinical utility of pharmacogenetic testing for prevention is unestablished.^[7]

DSM-5-TR classifies tardive dystonia within medication-induced movement disorders, alongside tardive dyskinesia and tardive akathisia. The diagnosis is clinical, anchored to exposure history and phenomenology.

Core criteria

• Involuntary movements that are dystonic in character, with sustained or intermittent muscle contractions producing twisting, repetitive movements or abnormal postures.^[9]
• Exposure to a dopamine receptor blocking agent for at least several months, or for at least one month in patients aged 60 or older.^[9]
• Onset during exposure or within 4-8 weeks of dose reduction or discontinuation of the offending agent.^[9]
• Persistence of symptoms for at least one month after the diagnostic assessment, distinguishing tardive dystonia from acute and subacute dystonic reactions.^[9]
• Symptoms are not better explained by a primary neurologic disorder, another medication, or a general medical condition.^[9]

Specifiers and severity

• Distribution is descriptive rather than codified: focal (single body region), segmental (two or more contiguous regions), multifocal (two or more noncontiguous regions), hemidystonia, or generalized.^[4]
• Severity is graded on the AIMS for global tardive burden and on dystonia-specific instruments such as the BFMDRS for severity and disability.^[10]

ICD-11 considerations

• ICD-11 codes tardive dystonia under 8A02 (dystonia) with a secondary cause modifier, separating it from primary dystonias in a way DSM-5-TR does not emphasize.^[11]
• Clinical implication: ICD-11 framing aligns with neurology practice and supports cross-specialty communication when patients are referred to movement disorders clinics.^[11]

Tardive dystonia produces sustained, often painful postures that can affect any body region but show characteristic patterns. The cervicocranial region is most commonly involved, and the phenotype frequently includes features that would be unusual in primary dystonia.

Typical distribution

• Cervical dystonia with retrocollis (head pulled backward) is the single most characteristic pattern, present in a majority of cases in published series.^[1,4]
• Cranial involvement with blepharospasm, oromandibular dystonia, or tongue-protrusion dystonia, often coexisting with classic tardive dyskinesia movements.^[1,4]
• Truncal involvement producing opisthotonic posturing, lateral trunk flexion (Pisa syndrome), or anterocollis with camptocormia in advanced cases.^[1,4]
• Limb dystonia is less common at onset but can develop with disease progression.^[1]

Phenomenology

• Sustained or patterned, in contrast to the brief, dance-like choreiform movements of tardive dyskinesia.^[4]
• Often painful, particularly cervical and truncal forms, an important distinction from largely painless tardive dyskinesia.^[4]
• May worsen with voluntary action (action dystonia) or specific tasks.^[4]
• Sensory tricks (geste antagoniste), in which a light touch to the chin or back of the head transiently improves posture, occur but are less reliable than in primary cervical dystonia.^[4]
• Persists during sleep less reliably than primary dystonia; many tardive dystonias attenuate during sleep.^[4]

Course markers

• Onset is insidious, often noticed first by family or staff rather than the patient.^[1,4]
• Progression over months to years is typical if the offending agent is continued, with eventual fixation of postures in long-standing cases.^[1,4]
• Spontaneous remission occurs in a minority of patients, roughly 10-20% in long-term follow-up, and generally requiring discontinuation of the offending agent.^[1,12]

The central diagnostic task is distinguishing tardive dystonia from other tardive syndromes, acute drug-induced dystonias, and primary or secondary dystonias unrelated to medication. Misclassification matters because management diverges sharply.

Other tardive syndromes

• Tardive dyskinesia in its classic oral-buccal-lingual form produces brief, repetitive, choreiform movements without sustained posturing; pain is uncommon, and onset skews older and female.^[1,4]
• Tardive akathisia is subjective restlessness with semi-purposeful movement; phenomenology is wholly different from dystonia but the two can coexist.^[4]
• Tardive tremor and tardive myoclonus are rarer; the movement is rhythmic or jerk-like rather than sustained.^[4]

Acute and subacute drug-induced reactions

• Acute dystonic reaction occurs within hours to days of starting or escalating a dopamine receptor blocking agent; oculogyric crisis and torticollis predominate, and the response to anticholinergics is rapid.^[4]
• Neuroleptic malignant syndrome is distinguished by hyperthermia, severe rigidity, autonomic instability, and altered mental status with markedly elevated creatine kinase.^[4]
• Serotonin syndrome features hyperreflexia, clonus, and a different temporal relationship to serotonergic agents.^[4]

Primary and secondary dystonias

• Adult-onset focal dystonias such as primary cervical dystonia and blepharospasm can phenotypically resemble tardive dystonia; the distinguishing feature is the exposure history.^[4]
• Wilson disease must be excluded in any patient under 50 with new-onset dystonia, with ceruloplasmin, 24-hour urinary copper, and slit-lamp examination for Kayser-Fleischer rings.^[13]
• Huntington disease typically presents with chorea but can include dystonic features; a family history and genetic testing clarify the diagnosis.^[13]
• Other genetic dystonias (DYT1, DYT6) usually present in childhood or adolescence with limb-onset progression.^[13]

Medical mimics worth screening for

• Hypocalcemia, hypomagnesemia, and hypoparathyroidism can produce tetany resembling dystonia.^[13]
• Autoimmune encephalitis (notably anti-NMDA receptor encephalitis) can include dystonic movements in a young patient with psychiatric features and a recent functional decline.^[13]
• Functional movement disorder (formerly psychogenic dystonia) is suggested by inconsistency, distractibility, and incongruence with known dystonic patterns.^[13]

Assessment centers on a complete exposure history, a structured motor examination, and targeted workup to exclude mimics. Standardized scales document baseline severity and response to treatment.

History elements

• Cumulative exposure to every dopamine receptor blocking agent the patient has received, including antiemetics, since many patients do not consider metoclopramide a psychiatric medication.^[5]
• Temporal relationship between exposure changes and movement onset, including any acute dystonic reactions or akathisia early in treatment.^[1,4]
• Family history of dystonia, parkinsonism, or other movement disorders, which can raise suspicion for an underlying genetic vulnerability or primary dystonia.^[13]
• Functional impact: pain, swallowing, breathing, gait, communication, employment, and social participation.^[10]

Examination

• Observe at rest, during conversation, and during action (writing, drinking, walking) to characterize distribution and triggers.^[10]
• Identify sensory tricks and document responsiveness; this both supports diagnosis and informs counseling.^[4]
• Test for coexisting tardive dyskinesia, parkinsonism, and akathisia, all of which can occur together.^[4]
• Look specifically for ocular features such as Kayser-Fleischer rings on slit-lamp examination if Wilson disease is plausible.^[13]

Rating scales

• AIMS for overall tardive burden, particularly useful for serial monitoring; less sensitive to dystonic posture than to dyskinesia.^[10]
• BFMDRS for severity and disability across body regions.^[10]
• Toronto Western Spasmodic Torticollis Rating Scale for predominantly cervical presentations.^[10]

Labs and imaging

• Routine MRI of the brain when the presentation is atypical, asymmetric, focal, or progressive despite agent withdrawal.^[13]
• Ceruloplasmin and 24-hour urinary copper in patients under 50, even without classic Wilson features.^[13]
• Calcium, magnesium, parathyroid hormone, and thyroid function when the exam suggests metabolic contribution.^[13]
• Genetic testing for primary dystonias when family history, age of onset, or distribution is atypical.^[13]

What not to order

• Routine electroencephalography is not useful in tardive dystonia and should be reserved for cases with paroxysmal features suggesting an epileptic disorder.^[13]
• Dopamine transporter imaging is not indicated and does not distinguish tardive from primary dystonia.^[13]

Management combines reduction of dopamine receptor blockade where psychiatrically safe, symptomatic suppression of dystonia, and targeted interventions for focal disabling features. No agent reliably reverses long-standing tardive dystonia, so early and stepwise treatment matters.

General principles

• Reassess the indication for the offending dopamine receptor blocking agent, recognizing that abrupt discontinuation can produce withdrawal-emergent dyskinesia and psychiatric decompensation.^[4,14]
• Where antipsychotic treatment must continue, switch to an agent with lower D2 affinity, typically clozapine or quetiapine, although evidence for switching strategies is limited.^[6,14]
• Initiate symptomatic therapy in parallel with any agent change; do not wait months to see whether withdrawal alone produces remission.^[14]
• Set realistic goals with the patient and family: partial improvement in posture, pain, and function rather than complete resolution.^[4,14]

Pharmacotherapy

• VMAT2 inhibitors are first-line for moderate to severe tardive syndromes, with valbenazine 40-80 mg PO QD and deutetrabenazine 12-48 mg PO in divided doses both FDA-approved for tardive dyskinesia and used off-label for tardive dystonia, where evidence is more limited but accumulating.^[14-16]
• tetrabenazine 12.5-100 mg PO in divided doses has the longest clinical track record in tardive dystonia and remains widely used outside the United States; depression and parkinsonism are dose-limiting.^[14,17]
• Anticholinergics including trihexyphenidyl 2-15 mg PO in divided doses and benztropine 1-6 mg PO often improve tardive dystonia, in contrast to their negative effect on tardive dyskinesia; cognitive load and anticholinergic burden limit dosing in older patients.^[4,14]
• baclofen 10-80 mg PO in divided doses and benzodiazepines such as clonazepam 0.5-4 mg PO in divided doses provide adjunctive relief, particularly for pain and segmental involvement.^[4,14]
• clozapine 12.5-450 mg PO warrants special mention: limited but consistent evidence suggests it can both substitute for the offending agent and reduce dystonia severity, making it a preferred switch in refractory psychotic illness.^[6,14]

Botulinum toxin

• Local injection of botulinum toxin type A is first-line for focal and segmental tardive dystonia, particularly cervical and cranial involvement.^[14,18]
• Onset of benefit is typically 1-2 weeks, peak effect at 4-6 weeks, with reinjection every 12-16 weeks.^[18]
• Evidence from focal primary dystonia trials supports efficacy; trials in tardive dystonia are smaller but show consistent benefit for cervical, blepharospasm, and oromandibular phenotypes.^[14,18]
• Adverse effects are usually local, including focal weakness, dysphagia with cervical injections, and ptosis with periocular injections, and are reversible.^[18]

Psychotherapy

• No psychotherapy directly treats tardive dystonia, but cognitive behavioral and supportive interventions are important for the depression, demoralization, and functional impact that frequently accompany it.^[14]
• Physical therapy and occupational therapy improve range of motion, prevent contractures, and adapt activities of daily living for fixed postures.^[14]
• Pain-focused interventions, including coordinated care with chronic pain services, are often necessary for cervical and truncal involvement.^[14]

Neuromodulation

• Deep brain stimulation of the bilateral internal globus pallidus is the most studied surgical intervention; case series and small controlled studies report substantial reduction in BFMDRS scores in medication-refractory tardive dystonia.^[8,19]
• Patient selection emphasizes severe, disabling dystonia refractory to optimized medical therapy, psychiatric stability sufficient to tolerate surgery and follow-up, and absence of cognitive impairment that would compromise consent.^[19]
• ECT has occasionally been reported to improve tardive dystonia, primarily when used for a coexisting mood or psychotic indication; evidence is limited to case series.^[14]
• Repetitive transcranial magnetic stimulation has been investigated for primary dystonia but is not established for tardive dystonia.^[14]

Adjunctive

• Vitamin E was historically studied for tardive syndromes; meta-analyses show no convincing benefit for established tardive dyskinesia or dystonia, though it remains low-risk.^[20]
• Branched-chain amino acids, ginkgo biloba, and melatonin have small studies in tardive dyskinesia with mixed results; data specific to tardive dystonia are minimal.^[20]
• Levetiracetam, zonisamide, and amantadine have small open-label series but no robust controlled evidence in tardive dystonia.^[14]

Treatment of tardive dystonia carries meaningful adverse-effect burden, and the evidence base is narrower than that for tardive dyskinesia. Most pivotal trials enrolled patients with predominantly choreiform tardive dyskinesia, and dystonia-predominant cases are underrepresented.

Common adverse effects of pharmacotherapy

• VMAT2 inhibitors commonly cause somnolence, dose-dependent parkinsonism, and akathisia, with rates rising at higher doses.^[15-16]
• Anticholinergics produce dry mouth, constipation, urinary retention, blurred vision, and cumulative cognitive impairment, particularly in older adults.^[4,14]
• Tetrabenazine and to a lesser extent deutetrabenazine and valbenazine can precipitate or worsen depression; baseline and ongoing screening is required.^[14,16-17]
• Benzodiazepines and baclofen contribute sedation, falls risk, and dependence with long-term use.^[14]

Serious or rare adverse effects

• VMAT2 inhibitors prolong the QTc interval; baseline electrocardiography is reasonable in patients with cardiac risk factors or concurrent QT-prolonging medications.^[15-16]
• Tetrabenazine carries an FDA boxed warning for depression and suicidality in Huntington disease; the same caution applies in psychiatric populations.^[17]
• Clozapine carries risk of agranulocytosis, myocarditis, seizures, ileus, and metabolic syndrome; mandatory hematologic monitoring applies.^[6]
• Botulinum toxin can produce dysphagia from cervical injections, with rare aspiration; weakness is dose-dependent.^[18]
• Deep brain stimulation carries surgical risks including infection and intracranial hemorrhage, plus stimulation-related dysarthria and gait change.^[19]

Monitoring, withdrawal, and discontinuation

• Withdrawal of the offending antipsychotic can precipitate rebound dyskinesia, transient worsening of dystonia, and psychiatric decompensation; taper gradually.^[14]
• VMAT2 inhibitors should be reduced gradually if discontinuation is needed to avoid recurrence of movements.^[14-16]
• Document baseline AIMS and a dystonia-specific scale before treatment changes to allow objective tracking of response.^[10]

Limitations of the evidence base

• Most randomized trials enroll patients with classic tardive dyskinesia phenotypes; dystonia-predominant cases are an underrepresented subgroup.^[14-16]
• Long-term outcome data beyond two to four years are sparse for VMAT2 inhibitors.^[15-16]
• Deep brain stimulation evidence is dominated by case series; controlled trials are small and short.^[8,19]
• Few head-to-head comparisons exist between VMAT2 inhibitors, anticholinergics, and botulinum toxin for dystonic features.^[14]

Tardive dystonia management changes meaningfully across age groups, pregnancy, and comorbid medical illness. Risk-benefit calculations diverge from those that apply to younger non-pregnant adults.

Pediatric and adolescent patients

• Tardive movement disorders occur in children and adolescents exposed to antipsychotics and antiemetics, with cumulative exposure as a major driver.^[2,4]
• Risk-benefit assessment should reassess every antipsychotic indication in pediatrics, including off-label use for irritability, aggression, and sleep.^[2]
• VMAT2 inhibitors are not FDA-approved in pediatrics, and pediatric trial data are limited; off-label use requires specialist consultation.^[15-16]

Geriatric patients

• Older adults face higher overall tardive risk per unit exposure and tolerate anticholinergics poorly; cognitive load, falls, and constipation often preclude effective doses of trihexyphenidyl.^[4,14]
• VMAT2 inhibitors carry parkinsonism and depression risk that compound geriatric vulnerability; start low and monitor gait and mood at each visit.^[14,16]
• Polypharmacy review at every encounter, including hidden dopamine receptor blocking agents such as metoclopramide and prochlorperazine.^[5]

Perinatal patients

• Pregnancy alters risk for both the underlying psychiatric illness and the movement disorder; tetrabenazine is contraindicated in pregnancy and lactation, and valbenazine and deutetrabenazine have limited pregnancy data.^[16-17]
• Coordinate with maternal-fetal medicine and reproductive psychiatry before any agent change to balance teratogenic risk, dystonia severity, and psychiatric relapse risk.^[14]

Comorbid medical illness

• Hepatic impairment requires dose adjustment of VMAT2 inhibitors; check current prescribing information at the time of treatment initiation.^[15-16]
• QTc-prolonging conditions and co-prescribed QT-prolonging drugs warrant baseline and follow-up electrocardiograms when using VMAT2 inhibitors.^[16]
• Swallowing dysfunction from oromandibular or pharyngeal dystonia is an aspiration risk; involve speech-language pathology early.^[14]

Comorbid substance use

• Stimulant use can worsen tardive symptoms and complicate response to VMAT2 inhibitors; integrate substance use treatment with movement disorder care.^[14]
• Alcohol use is a relative contraindication to high-dose benzodiazepines used for symptomatic relief.^[14]

Cultural and access considerations

• Awareness of tardive syndromes varies internationally; underrecognition is documented in primary care and long-term-care settings.^[1,4]
• Access to botulinum toxin, VMAT2 inhibitors, and deep brain stimulation is uneven, and treatment plans should be calibrated to what the patient can actually receive.^[14]

Tardive dystonia is more often persistent than remitting. Functional and quality-of-life outcomes are substantial, and a minority of patients improve with discontinuation of the offending agent.

Natural history

• Spontaneous remission in roughly 10-20% of patients followed for several years, generally requiring sustained reduction or discontinuation of the offending agent.^[1,12]
• Persistence or progression in the majority if the offending agent is continued at full dose.^[1,12]
• Onset of new body regions of involvement over time is common in untreated cases, with cervical-onset patients later developing cranial or truncal features.^[1]

Functional outcome

• Pain, particularly cervical and truncal, is a major driver of disability and reduces health-related quality of life.^[10]
• Employment loss, social withdrawal, and depression occur in a substantial fraction of patients and are independently associated with severity.^[10,14]
• Suicide risk is elevated in tardive dystonia compared with the general population, with severity, pain, and comorbid depression as contributors.^[14]

Response to treatment

• VMAT2 inhibitors produce moderate reductions in tardive dyskinesia severity over 6-12 weeks; dystonia-specific response is less consistently quantified, with smaller series suggesting partial benefit.^[15-16]
• Botulinum toxin produces clinically meaningful improvement in focal cervical and cranial dystonia in most patients, sustained with regular reinjection.^[14,18]
• Deep brain stimulation produces large reductions in BFMDRS scores in selected refractory patients, with most responders maintaining benefit at 3-5 years.^[8,19]

Tardive dystonia is rarely a life-threatening emergency, but certain presentations require urgent attention to airway, breathing, swallowing, and pain.

Acute escalations

• Status dystonicus, also called dystonic storm, is a rare but life-threatening generalized worsening with rigidity, hyperthermia, rhabdomyolysis, and respiratory compromise; manage in an intensive care setting with sedation, hydration, and movement disorders consultation.^[13-14]
• Acute airway compromise from laryngeal or severe oromandibular dystonia requires immediate otolaryngology and anesthesia involvement.^[14]
• Severe dysphagia with aspiration risk warrants nothing-by-mouth status and speech-language pathology evaluation before resuming oral intake.^[14]

Hospitalization considerations

• Suicidal ideation associated with the burden of tardive dystonia is itself an indication for psychiatric admission when risk is acute.^[14]
• Severe pain refractory to outpatient management may justify admission for botulinum toxin injection, intensive physical therapy, and analgesic optimization.^[14]
• Hospitalization for an unrelated medical or surgical reason is an opportunity to review every dopamine receptor blocking agent on the medication list and document tardive findings before they are wrongly attributed to delirium.^[5,14]

Several aspects of tardive dystonia management remain contested, reflecting a thin randomized evidence base in a disorder that overlaps clinically with the broader tardive syndromes.

Open questions

• Whether second-generation antipsychotics confer a clinically meaningful reduction in risk of tardive dystonia compared with first-generation agents, with cohort data suggesting a partial but incomplete protective effect.^[2-3]
• Whether VMAT2 inhibitors, with strong evidence for tardive dyskinesia, are equally effective for predominantly dystonic phenotypes; head-to-head trials in tardive dystonia are lacking.^[14-16]
• Whether switching to clozapine independently improves tardive dystonia or simply allows reduction of the original offending agent; existing data do not separate these effects cleanly.^[6,14]
• The optimal timing of deep brain stimulation referral relative to medical therapy, with some experts favoring earlier intervention before postures fix.^[8,19]
• The role of pharmacogenetic testing (notably CYP2D6) in predicting risk; evidence is suggestive but does not currently support routine clinical use.^[7]

Regulatory and labeling debates

• Metoclopramide carries an FDA boxed warning for tardive movement disorders, but population data suggest continued widespread prescribing, particularly in primary care and gastroenterology settings.^[5]
• VMAT2 inhibitors are FDA-approved for tardive dyskinesia but not specifically for tardive dystonia, leaving prescribers reliant on off-label use with payer-related access barriers.^[15-16]

Emerging directions

• Refinement of DBS targets, including subthalamic nucleus as an alternative to internal globus pallidus, with small comparative series.^[19]
• Investigation of newer dopamine partial agonists and serotonin-dopamine modulators for both prevention and treatment, though large-scale tardive dystonia data are not yet available.^[14]

• Tardive dystonia is a delayed movement disorder caused by chronic exposure to dopamine receptor blocking agents, presenting after months to years of treatment.^[1,4]
• Cervical retrocollis is the single most characteristic phenotype, often with cranial involvement such as blepharospasm or oromandibular dystonia.^[1,4]
• Tardive dystonia skews toward younger men, the opposite demographic pattern from classic tardive dyskinesia, which favors older women.^[1,4]
• Anticholinergics often improve tardive dystonia but worsen tardive dyskinesia.^[4]
• Acute dystonic reaction occurs within hours to days of starting a dopamine receptor blocking agent; tardive dystonia requires months of exposure.^[4]
• Metoclopramide carries an FDA boxed warning for tardive movement disorders and is a frequently overlooked cause.^[5]
• Clozapine has the lowest reported risk of tardive syndromes and is a preferred switch agent in refractory psychotic illness with tardive dystonia.^[6]
• VMAT2 inhibitors (valbenazine, deutetrabenazine, tetrabenazine) are first-line pharmacotherapy for moderate to severe tardive syndromes.^[14-16]
• Botulinum toxin type A is first-line for focal and segmental tardive dystonia, particularly cervical, blepharospasm, and oromandibular phenotypes.^[14,18]
• Deep brain stimulation of the bilateral internal globus pallidus is the most studied surgical intervention for medication-refractory tardive dystonia.^[8,19]
• Wilson disease must be excluded in any patient under 50 with new-onset dystonia via ceruloplasmin, 24-hour urinary copper, and slit-lamp examination.^[13]
• Coexistence of tardive dyskinesia and tardive dystonia occurs in roughly half of patients with tardive dystonia.^[1,4]
• Spontaneous remission of tardive dystonia occurs in only 10-20% of patients after agent discontinuation.^[1,12]
• Vitamin E is not effective for established tardive syndromes despite historical interest.^[20]

No external funding. No conflicts of interest declared. Peer-review status: pending.